The goal of this observational study is to identify newborns at increased genetic risk of developing type 1 diabetes-specific beta-cell autoantibodies in order to determine eligibility for participation in primary prevention randomized controlled trials aimed at preventing beta-cell autoimmunity.
Screening is performed between the ages of 0 and 6 weeks.
Consent form signed by parents/guardian.
Infants aged above 6 weeks.
Refusal to participate in the study
This study includes infants aged between 0 and 6 weeks, both male and female.
Cohort
Cross-sectional
Not listed
Identification of Infants at Risk Greater than 10% for Beta-Cell Autoimmunity and Type 1 Diabetes
Risk score derived from single nucleotide polymorphisms (SNPs) used to identify participants at increased genetic risk.
Click on the lead sponsor to view all of their trials.
IRCCS San Raffaele
Lead sponsor
Clinica Mangiagalli
Collaborator
Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Collaborator
Azienda Socio Sanitaria Territoriale di Lecco
Collaborator
Ospedale F. Del Ponte, Varese
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
